Eurofins Discovery

Our Eurofins Discovery St. Charles, MO site recently rallied together for an important local charity providing support for victims of domestic violence, Lydia’s House in St. Louis. Through our collective efforts, we've contributed to needed items to support women and children on their journey toward healing and sustainable futures. We were happy to be part of this initiative and grateful to everyone who contributed from our team. It was gratifying to assist an organization that has truly made a meaningful impact on the lives of our neighbors navigating challenging circumstances. This experience reinforces Eurofins Discovery’s commitment to giving back to our community and fostering positive change where it's needed most. Together, we're making a difference—one act of kindness at a time.

Throwback Thursday ➡ Important moments in the history of Secondary Pharmacology! 💡 As we discuss the new opportunities brought about from recent recommendations in evaluating the safety of molecules, it is interesting to take a step back and look at where we are today and one of the important moments influencing how we arrived here. Most people working in Drug Discovery are very familiar with the 2012 publication: Bowes, J. et al., Reducing safety-related drug attrition: the use of in vitro pharmacological profiling in Nature Reviews Drug Discovery. The most significant targets presenting potential risks identified in this research have been instrumental in shaping the way novel molecules are evaluated and believed to be a major contributing factor in the improved safety profile of new drugs brought to market. Eurofins Discovery, with industry-leading panels including SafetyScreen44 and SAFETYscan47, has supported biotech and pharmaceutical partners for decades in evaluating the off-target liabilities of innovative treatments. We continue to provide a wide range of Safety Pharmacology solutions for every stage of drug discovery: https://lnkd.in/dmXvFyZT What are some of the reasons that our clients choose to collaborate with us? ·  We have decades of experience leading the market with robust secondary pharmacology solutions. ·  The SafetyScreen™ brand is known for high-quality, robust assays producing reliable results. ·  Our solutions fully adhere to FDA and industry recommendations. ·  We pay attention to developments in the industry and strive to provide adapted solutions. Did you know that our comprehensive safety offer includes highly specialized panels? ·  CiPA-compliant Cardiac Safety: https://lnkd.in/dGECA_89 ·  Biology-first Approach with Validated Toxicity Signature Analysis and Safety Portfolio: https://lnkd.in/dexyKSTN ·  Specialized Pre-IND and Specialty In Vitro Profiling Panels: https://lnkd.in/dYt9q9eG ·  Hit-to-Lead & Lead Optimization Panels: https://lnkd.in/dZkYUGT9 ·  ADME-PK and Tox: https://lnkd.in/dFcvic5R Reach out if you would like to discuss a project – our experts are here to help! #Eurofins #ThrowbackThursday #TBT #Pharmacology #DrugDiscovery #SafetyPharmacology #CiPA #ADME SAFETYscan® is a Eurofins Discovery Registered Trademark 

Need your data ASAP? Eurofins Discovery’s SAFETYscan™47 is offered at an expedited turnaround time of 15 business days from scheduled panel run, allowing you to receive your data as fast as possible. The SAFETYscan47 functional panel includes targets and pathways which are well established as contributors to clinical adverse drug reactions (ADRs), that may be used in different stages of drug discovery for early safety evaluation of drug candidates in line with clinical adverse event predictions. With a focus on efficiency and accuracy, SAFETYscan47 represents a breakthrough in modern chemical safety evaluation. Key features: ✔ 78 assays covering a broad range of targets including ion channels, receptors, enzymes and transporters ✔ All human targets ✔ Option for expedited 15-business-day turnaround time ✔ Functional assessment of relevant drug liability targets for early hazard identification, off-target mitigation and to predict clinical adverse effects to reduce unwarranted attrition Eurofins Discovery offers additional safety capabilities, like our SafetyScreen44™ panel with binding and enzymatic capabilities, our high-throughput in vitro phenotypic assay using hiPSC-derived cardiomyocytes, and Tier 2 & Tier 3 Safety Pharmacology Profiling SafetyScreen panels. Order now: https://lnkd.in/gffSwWTu #SafetyPharmacology #SafetyPanel #SafetyScreen #Safetyscan47

GO GREEN TEAM! Celebrating the dedicated Eurofins Discovery team volunteers at our science campus in St. Charles, Missouri, for their hard work “cleaning up the neighborhood” clearing litter, debris and even a lost hubcap in our continuing effort to preserve green space. For years, our team has proudly maintained this scenic stretch of roadside as part of our unwavering commitment to sustainability and environmental stewardship, contributing to beautifying our surroundings and supporting the Missouri Department of Transportation efforts to Keep Missouri Beautiful. Our team continues our commitment to Eurofins Discovery/Eurofins Panlabs corporate responsibility, and our enduring dedication to giving back to our community.

🌟 Exciting News in Secondary Pharmacology! 🌟 The Preclinical Safety Leadership Group (DruSafe), composed of senior preclinical safety assessment leaders from IQ Consortium member companies, has recently published the findings of an in-depth survey of current practices in secondary pharmacology. Based on their research, the DruSafe working group makes a number of recommendations to refine drug safety and efficacy benchmarks. As an industry leader in in vitro safety assessment, Eurofins Discovery has been at the forefront for decades, supporting innovation in the field with our extensive expertise, and these recent findings are no exception! 🔗 Read the new Nature Reviews Drug Discovery publication: https://lnkd.in/gi29nb8D Eurofins Discovery stands out with its extensive portfolio of hundreds of off-the-shelf, fully validated, and QCed assays under the SafetyScreen™ brand with renowned SafetyScreen 44 and SAFETYscan® 47 panels as well as custom safety panels. Our high-quality results and comprehensive services align perfectly with the latest industry and regulatory recommendations. 💡 New SafetyScreen panels in alignment with the DruSafe publication will complement our rich portfolio in the coming weeks, providing support to all stages of the drug discovery workflow, from Hit-to-Lead to Lead Optimization and Candidate Selection. Together, we're at the forefront of creating safer, more effective medicines. We are here to support all of your in vitro secondary pharmacology needs. Learn more about our comprehensive SafetyScreen portfolio: https://lnkd.in/gX6wkpsU #Eurofins #Pharmacology #DrugDiscovery #Innovation #SafetyPharmacology #CiPA #ADME #Toxicology #HitToLead #LeadOptimization

🌐 The Eurofins network is built on trust. Our clients expect the highest level of integrity and competence from each Eurofins entity and employee.   ⚖️ Compliance with all relevant regulations is enhanced by embedding the value of integrity in the culture of our organization.   📝 Read about the Eurofins network’s framework for transparency, accountability, and ethical decision-making in the ‘Governance’ section of our ESG Report 2023: https://lnkd.in/drriKtEh   #Eurofins #ESG #Governance #Sustainability #TestingForLife

Be sure to follow Eurofins so you do not miss this month's series of employee stories highlighting pride, unity, hope, and celebration!

Pioneering innovation in oncology drug discovery! 💡 At Eurofins Discovery, our enzyme team in Taiwan has engineered cutting-edge drug screening platforms targeting vital enzymes with high therapeutic potential, to help speed up the anti-cancer drug development process. From RAS to PARP and ENPP families, our LeadHunter Panels offer comprehensive screening for potential inhibitors: 🔬 RAS Human Variant LeadHunter Panel covers broad RAS isoforms and the most common mutations. 🔬 PARP Screen LeadHunter Panel contains PARP subtypes that are highly engaged in gene damage repair and innate immunity. 🔬ENPP Screen LeadHunter Panel includes all ENPP subtypes from ENPP1 to ENPP7. Explore our RAS Drug Discovery and STING Pathway initiatives and let our experienced scientists lead you to the next anti-cancer breakthrough. Together, we're shaping the future of cancer treatment! 🦠 https://lnkd.in/g9y3SDyj #EurofinsAsia #OncologyInnovation #DrugDiscovery #EnzymeResearch #CancerBreakthroughs

How familiar are you with Chemistry drug discovery services from Eurofins Discovery?

Client visits focusing on #Biotherapeutics! 💡 A cloudy sky was not enough to put a damper on the enthusiastic discussions that Francisca Neethling, Monika Chojnowska-Monga and Santosh Krishna Subramanian PhD had this week with clients in Cambridge, UK. The team thoroughly enjoyed the in-depth exchanges about antibody characterization by binding and functional assays, cytotoxicity, affinity binning and ADC testing in different cell types, which provided valuable information to move key projects forward in the coming weeks. Are you looking for discovery support for your biotherapeutics project? Reach out to our team or visit our website for more information: https://lnkd.in/gCczKWxR #Eurofins #DrugDiscovery #GeneTherapy #Biologics #Antibodies